COVID-19 is affecting the biopharma industry in myriad ways, including short-term disruption to R&D programs and clinical trials, but also causing complications in the commercial arena and to supply chains. This is evident in the near-absence of M&A transactions completed through the first half of the year, although an extremely healthy environment for fundraising via public offerings and venture capital provides balance and opportunity.
In August 2020 Informa Connect and Pharma Intelligence partnered to conduct an online survey to gauge perspectives around deal-making during COVID-19 and the commercial ramifications of the pandemic. This report, based on the responses of 173 executives, business development, and licensing professionals, reveals how partnering discussions have evolved through necessity, and proposes the future direction of deal-making, a strategic imperative for any successful company.
By Daniel Chancellor, Thought Leadership Director at Pharma Intelligence, who also offers insights throughout the report.